Prelaunch activity of Metformin+Glimepiride combination

MARKET SURVEY OF DOCTOR PREFERENCE ON
GLIMEPIRIDE + METFORMIN AS A PART OF
PRELAUNCH ACTIVITY AT MEDPAAR
PHARMACEUTICALS
A PROJECT REPORT
On behalf of
MEDPAAR PHARMACEUTICALS
Submitted by
AMITSINH VIHOL
in partial fulfillment for the award of the degree
of
MASTER OF BUSINESS ADMINISTRATION
IN
PHARMA MANAGEMENT
Under the guidance of
GUIDE CO-GUIDE
Dr. Shrikalp S. Deshpande Mr. Charming A. Vakil
KADI SARVA VISHWA VIDYALAYA.
APRIL 2014

PFIARMACET]TICALS
Reg.&CorporateOffice: TF- 07,3" Floor,Agrawal.Mall,Opp.BhagwatVidhyapith,9c. Highway,Sola,Ahmedabad-38oo60(Gujarat)
Ph: 9033649833,9724352581website:wwwmedpiarptrarmi.cbm,Emait:-medfaarpharma@gmail.com
Date:l-5'nApril,2OI4
TOWHOMSOEVERITMAYCONCERN
Thisisto certifythat Mr. AMITSINHV|HOLfromKADISARVAVISHWAVIDYALAYAMBA
PHARMA,GANDHINAGARhas successfullycompletedhis major projectin our companyon
,,MARKET
SURVEYOF DOCTORPREFERENCEON GLIMEPIRIDE+METFORMINAS A PARTOF
PRELAUNCHACTIVITYAT MEDPAARPHARMACEUTICALS,,fTOM5.NDCCCMbCT,2OT3tO 15.h
April,2014,
Duringhistenureof internship,we found him sincereand hardworking.We wish him all the
bestfor future endeavors.
ForMedpaarPharmaceuticals,Ahmedabad

CERTIFICATE
This is to certify that Mr. AMITSINH VIHOL, Reg. No.
1214MBAP19043, is a student of final year MBA[Pharma] and has submitted the
project report titled “MARKET SURVEY OF DOCTOR PREFERENCE ON
GLIMEPIRIDE + METFORMIN AS A PART OF PRELAUNCH ACTIVITY
AT MEDPAAR PHARMACEUTICALS”, in partial fulfillment of the
requirements for the award of the degree of Master of Business Administration
[Pharma] during the academic year 2012-14.
Coordinator, Dean,
Mrs. Mallika Babu Dr. Gaurang B.Shah
[M.Sc., MBA] [Ph.D., CCA]
Department of Pharmaceutical Management, Pharmaceutical Sciences,
KSV University, Gandhinagar. KSV University, Gandhinagar.

GUIDE CERTIFICATE
This is to certify that the project report titled “MARKET SURVEY OF
DOCTOR PREFERENCE ON GLIMEPIRIDE + METFORMIN AS A PART
OF PRELAUNCH ACTIVITY AT MEDPAAR PHARMACEUTICALS”,
submitted for fulfillment of the requirement for the award of the Degree of Master
of Business Administration [Pharma], is the bonafide work of “Mr. AMITSINH
VIHOL” who carried out the project work under my supervision.
CO-GUIDE GUIDE
Mr. CHARMING A. VAKIL Dr. SHRIKALP S. DESHPANDE
[B.Pharm.; MBA Pharma] [Ph.D.;M.Pharm,]
Department of Pharmaceutical Management, Department of Pharmaceutical Science,
KSV University,Gandhinagar. KSV University,Gandhinagar.

Student Declaration
I hereby declare that the thesis titled “Market Survey of Doctor
Preference on Glimepiride + Metformin as a Part of Prelaunch Activity at
Medpaar Pharmaceuticals” submitted to Kadi Sarva Vishwa Vidyalaya in
fulfillment of the requirement for the award of the Degree of Master of Business
Administration [Pharma] with Marketing/HR Specialisation is a record of project
done by me under the guidance of Dr. Shrikalp Deshpande, Department of
Pharmaceutical Science, KSV University, Gandhinagar & Mr. Charming A. Vakil,
Department of Pharmaceutical Management, KSV University, Gandhinagar. It also
assures that this work is original and no part of this report has been submitted for
the award of any other degree/diploma/fellowship or similar titles or prizes.
Place:Gandhinagar
Date: Amitsinh Vihol

Pagei
ACKNOWLEDGEMENT
Every project big or small is successful largely due to the effort of a number
of wonderful people who have always given their valuable advice or lent a helping
hand. I sincerely appreciate the inspiration; support and guidance of all those people
who have been instrumental in making this project a success.
I, Amitsinh Vihol, the student of KSV MBA PHARMA GANDHINAGAR,
am extremely grateful to “MEDPAAR PHARMACEUTICALS” for the
confidence bestowed in me and entrusting my project entitled “Market Survey Of
Doctor Preference On Glimepiride + Metformin As A Part Of Prelaunch Activity At
Medpaar Pharmaceuticals” with special reference to Medpaar Pharmaceuticals.
At this juncture I feel deeply honored in expressing my sincere thanks to Mr.
Vilesh Patel (GM, Medpaar Pharmaceuticals) for making the resources available at
right time and providing valuable insights leading to the successful completion of
my project.
I express my gratitude to Dr. Gaurang. B. Shah (Dean, KSV MBA Pharma)
for arranging the major project in good schedule. I also extend my gratitude to my
Project Guide Dr. Shrikalp Deshpande (Guide, HOD Pharmacology Depart.,
KBIPER) and Mr. Charming A. Vakil (Co-guide, Faculty at KSV MBA Pharma),
who assisted me in compiling the project.
I would also like to thank Mrs. Mallika Babu (Co-ordinator, KSV MBA
Pharma), Mr. Hardik N. Patel (Faculty at KSV MBA Pharma) and Mr. Naresh
Poturaju (Faculty at KSV MBA Pharma) for their critical advice and guidance
without which this project would not have been possible.
Last but not the least I place a deep sense of gratitude to my parents, family
members and my friends who have been constant source of inspiration during the
preparation of this project work.
Amitsinh Vihol

Pageii
ABSTRACT
Glimepiride and Metformin combination is generally prescribed to the
diabetic patient. In order to achieve the objectives a survey of Doctors (Physicians,
General Practitioners) was conducted. Exploratory research was carried out.
Aim of the study was to study doctor preference on Glimepiride-Metformin
combination, to analyze the future market demand of this combination, to find out
the mostly prescribed strength of this combination, to know which brand of this
combination is superior in doctors and to analyze the brand and company selection
criteria for this combination.
In Data collection sources, Primary data were obtained from the field survey
of 120 doctors which included Physicians and General Practitioners by using
Convenience Sampling technique from North Gujarat Region (Mehsana,
Himatnagar,Visnagar, Vijapur). And secondary data were gathered from books and
Internet. Data was obtained on the basis of questionnaire filled and personal
interview with the doctors.
Data analysis of survey gave the interpretation that generally doctors prescribe
Glimepiride and/or Metformin in diabetes mellitus because of maximum therapeutic
effect and rapid action.
According to survey Zoryl (Intas-23.8%), Glycomet Gp (USV-23.8%),
Gemer (Sun-19%) and Gluconorm G (Lupin-13.3%) are mostly prescribed brands
for Glimepiride and Metformin combination. About 73% doctors prescribe
Glimepiride-1mg+Metformin-500mg.
During survey it was found that this combination have side effects like
hypoglycemia and stomach pain. Future Demand of Glimepiride+Metformin is high
as per doctors’ opinion.

Pageiii
Doctors find regular MR visit, scientific literature and samples for company
selection. According to doctors, company image, effectiveness and price are most
considerable factors for brand selection of Glimepiride+Metformin.
From this study we concluded that most doctors preferred
Glimepiride+Metformin for diabetes mellitus as a combination therapy in the
strength of Glimepiride-1mg+Metformin-500mg. Company image, effectiveness
and price are most considerable factors for brand selection.

Pageiv
INDEX
CHAPTER TITLE PAGE NO.
NO.
ACKNOWLEDGEMENT i
ABSTRACT ii
INDEX iv
LIST OF TABLE vii
LIST OF FIGURES viii
LIST OF ABBREVIATION ix
1. INTRODUCTION 1
1.1 Market Overview 1
1.2 Trends and Developments 2
1.3 Key Issues 3
1.3.1 Hospitals 3
1.3.2 Insurance 3
1.3.3 Pharmaceuticals 3
1.3.4 Government 4
1.4 New Market 5
1.4.1 Diabetes Market 5
1.4.2 Thrombosis Market 8
2. COMPANY PROFILE 9
2.1 Introduction 9
2.2 Company Profile 9
2.3 Company Vision 10
2.4 Company Mission 10
2.5Core Values 11
2.6 Working Strategy 11

Pagev
2.7 Our Team 11
2.8 Product Portfolio 12
3. LITERATURE REVIEW 14
3.1 Type 1 Diabetes 14
3.2 Type 2 Diabetes 14
3.3 Impaired Fasting Glucose 15
3.4 Treatment 15
4. RESEARCH METHODOLOGY 18
4.1 Plan of Work 18
4.2 Research Objective 18
4.3 Scope of Study 19
4.4 Research Methodology and Design 19
4.5 Data Collection Source 19
4.6 Data Collection and Analysis 19
4.7 Limitation 20
5. DATA ANALYSIS 21
5.1 Demographic Characteristics 21
5.2 Patient Consulting During a Day 22
5.3 Consulting Diabetic Patient during a Day 23
5.4 Mostly Prescribe Drug for Type-2 Diabetic Mellitus 24
5.5 Reason for Prescribing Glimepiride+Metformin Combination 26
5.6 More Prefer Brand for Glimepiride+Metformin: 27
5.7 Most Prescribing Strength of Gllimepiride+Metformin 29
5.8 Adverse Reaction with Glimepiride+Metformin 31
5.9 Opinion on Future Demand of Glimepiride+Metformin 32
5.10 Preference to Select Company 33
5.10.1 Regular visit of Medical Representative 33
5.10.2 Samples 34

Pagevi
5.10.3 Knowledge Update Program by the Company 35
5.10.4 Scientific literature provided by company 36
5.10.5 Scientific support from company 37
5.10.11 All criteria for selection of company 38
5.11 Considering Factors for Brand Selection 40
5.11.1 Price 40
5.11.2 Company image 41
5.11.3 Availability 42
5.11.4 Effectiveness 43
5.11.5 Unique Tablet formulation 44
5.11.6 Overall preference for selection of
Glimepiride+Metformin brand 45
6. FINDINGS 46
7. CONCLUSION 47
8. SUGGESTIONS 48
9. REFERENCE 49
10. APPENDIX 51

Pagevii
LIST OF TABLE
TABLE NO. NAME OF TABLE PAGE NO.
1.1 Indian Therapeutic Market 5
4.1 Plan of Work 18
5.1 Patient Consulting during a Day 22
5.3 Mostly Prescribe Drug for Type 2 Diabetes 24
5.4 Reason for Prescribing Gllimepiride+Metformin Combination 26
5.5 More Prefer Brandfor Gllimepiride+Metformin 27
5.7 Adverse Reaction with Gllimepiride+Metformin 31
5.8 Opinion on Future Demand 32
5.9 Preference to Select Company-Regular Visit of MR 33
5.10 Preference to Select Company-Samples 34
5.11 Preference to Select Company-Knowledge Update Program 35
5.12 Preference to Select Company-Scientific Literature by Company 36
5.13 Preference to Select Company-Scientific Support from Company 37
5.14 Overall Preference for Selection of Company 38
5.15 Brand Selection-Price 40
5.16 Brand Selection-Company Image 41
5.17 Brand Selection-Availability 42
5.18 Brand Selection-Effectiveness 43
5.19 Brand Selection-Unique Tablet Formulation 44
5.20 Overall Preference for Brand Selection 45

Pageviii
LIST OF FIGURES
FIGURE NO. NAME OF FIGURE PAGE NO.
5.1 Sample Distribution (Areawise) 21
5.2 Sample Distribution (Genderwise) 21
5. 3 Sample Distribution (Agewise) 21
5.4 Patient Consulting during a Day 22
5.6 Mostly Prescribe Drug for Type 2 Diabetes 24
5.7 Reason for Prescribing Gllimepiride+Metformin Combination 26
5.8 More Prefer Brandfor Gllimepiride+Metformin 27
5.10 Adverse Reaction with Gllimepiride+Metformin 31
5.11 Opinion on Future Demand 32
5.12 Preference to Select Company-Regular Visit of MR 33
5.13 Preference to Select Company-Samples 34
5.14 Preference to Select Company-Knowledge Update Program 35
5.15 Preference to Select Company-Scientific Literature by Company 36
5.16 Preference to Select Company-Scientific Support from Company 37
5.17 Overall Preference for Selection of Company 38
5.18 Brand Selection-Price 40
5.19 Brand Selection-Company Image 41
5.20 Brand Selection-Availability 42
5.21 Brand Selection-Effectiveness 43
5.22 Brand Selection-Unique Tablet Formulation 44
5.23 Overall Preference for Brand Selection 45

Pageix
LIST OF ABBREVIATIONS
CAGR- Compound Annual Growth Rate
GDP- Gross Domestic Product
CVD – Cardio Vascular Disease
DCGI- Drugs Controller General of India
GAD- Glutamic Acid Decarboxylase
IFG- Impaired fasting glucose
GP- General Practitioner
MR- Medical Representative

AMITSINH VIHOL | KSV MBA (Pharma) 2012-2014
Page1
CHAPTER 1: INTRODUCTION
India with over 63 million diabetics represents the world’s second largest
diabetes population after China. The Indian population that had faced under nutrition
for a long time is now exposed to over nutrition and sedentary lifestyles. Coupled
with a bad nutritional history and the fact that Indians are genetically more
vulnerable to diabetes compared to other population groups, India’s struggle with
diabetes is expected to be one of the biggest epidemics the country has ever
witnessed.
India’s diabetes statistics may ring alarm bells for the government and
healthcare authorities, for drug and diagnostic manufacturers, however, it represents
a goldmine. Fuelled by a continuous increase in the healthcare expenditures, the
market for diabetes drugs and diagnostics is expanding robustly in the country. This
is creating lucrative opportunities for global healthcare companies at a time when
growth rates in the more developed markets have declined.
1.1 Market Overview
In recent years, healthcare has become a priority for many countries, and India
is no exception. The rapid development of technology, diagnostic equipment and
treatments, coupled with people living longer and requiring more medical support
with age, is a reality.
With a population of more than 1.2 billion people, the Indian pharmaceutical
market is forecast to grow at a Compound Annual Growth Rate (CAGR) of 15.1%
(±4.0%) between 2011 and 2016, reaching USD23.3 billion by 2016 (IMS Market
Prognosis 2012). And as India’s economy continues to develop, the government is
starting to prioritize its healthcare sector.

 INTRODUCTION  CHAPTER 1
Page2
1.2 Trends and developments
As India moves towards its vision of improving access to basic healthcare,
increasing the availability of free essential medicines, broadening basic health
insurance coverage and boosting overall healthcare standards, several trends have
emerged:
 Expansion of Private Hospital Sector
Private healthcare access is no longer limited to major metros, tier-I cities and
prominent urban areas.
 Imposition of Price Controls
In a bid to regulate the prices of medicine, the government will be imposing
broader direct price controls and a market-based regulation will be applied to all
348 drugs on the National List of Essential Medicines.
 Issuance of Compulsory Licenses
The government aims to extend the sphere of patent protection to the areas of
pharmaceuticals, especially following the issuance of India’s first compulsory
license in March 2012.
 Growth of Promotional Tie-Ups
To aid in market penetration, Indian pharmaceuticals companies have seen an
increase in the number of promotional tie-ups between foreign and domestic
businesses.

Page3
1.3 Key Issues
As India gears towards a new future in healthcare, hospitals, pharmaceuticals
companies, insurance firms and the Indian government are hard pressed to address
the issues prevalent in each sector.
1.3.1 Hospitals
Over the years, sustained economic growth in India has fuelled a rising
demand for quality care, driving rapid expansion of the hospital sector. In line with
the government’s vision of making healthcare more accessible, India continues to
see a growth in the number and capabilities of both public and private hospital and
specialist clinic sectors.
1.3.2 Insurance
The continued growth and expansion of India’s population and economy has
driven the demand for, and development of, a burgeoning insurance industry. Intense
competition, inadequate fraud detection systems and product innovation are critical
challenges that must be addressed in order to secure longevity and profitability in
this market.
1.3.3 Pharmaceuticals
The pharmaceutical industry in India has taken a quantum leap with the rise
in incomes, higher literacy rates and increased consumer awareness. Local firms and
multinationals alike are challenged with identifying strategic new opportunities,
efficiently reaching their target market, and anticipating critical competitive forces.
The pharmaceutical industry in India has taken a quantum leap with the rise in
incomes, higher literacy rates and increasing consumer awareness.

Page4
Local firms and multinationals alike are challenged with identifying strategic
new opportunities, efficiently reaching their target market, and anticipating the
consequences of critical trends, including:
• Tightening government regulations, leading to a more stable regulatory
environment for companies.
• Increasing resources devoted to local brand building
• Broadening geographic coverage
These trends and developments are combining to form a remarkably new
landscape for pharmaceuticals companies to navigate as they work to create - and
validate - sustainable strategies.
1.3.4 Government
In recent years, the government has pushed addressing the lack of access to
adequate, quality, public healthcare to the top of its agenda, and has committed to
creating a standard that is on par with healthcare systems in developed countries.
With the rising incidence of chronic diseases, the challenge of ensuring an effective
utilization and distribution of India’s healthcare budget is more imperative than ever.
In recent years, the government has pushed addressing the lack of access to adequate,
quality, public healthcare to the top of its agenda, and has committed to creating a
standard that is on par with healthcare systems benchmarked in developed countries.
Currently, healthcare spending remains low at 4.2% of GDP, but rising patient
incomes and the government’s overall commitment to boost funding for the
improvement and expansion of the public health infrastructure will push this
spending up significantly in the coming years.

Page5
1.4 New Markets
The increasing influence of the Western culture has seen many young Indians
starting to adopt the lifestyle, especially in their food choices. As a result of this,
while communicable diseases continue to take a heavy toll, chronic diseases such as
cancer, diabetes, cardiovascular diseases and stroke are becoming increasingly
prevalent.
1.4.1 Diabetes Market[7][9][10][11]
The increasing rates of obesity and an aging population will increase the proportion
of Indians who are diabetic; by 2016 the market is estimated to be worth USD 1.76
billion. (IMS Market Prognosis 2012).
Table 1.1 Indian Therapeutic Market[10]
SUPERGROUP MAT VAL IN CRS MAT VAL GR JAN-14 MONTH JAN-14 MONTH GR
IPM 74452.2 5.8 6232.6 8.6
ANTI-INFECTIVES 12559.5 0.6 964.9 1.3
CARDIAC 9240.4 8.6 823.2 8.8
GASTRO INTESTINAL 8406.9 5.4 674.3 9.9
VITAMINS / MINERALS / NUTRIENTS 6592.8 4.8 531.2 10.9
RESPIRATORY 5848.1 9.1 543.7 9.8
PAIN / ANALGESICS 5363.6 3.7 428.7 5.8
ANTI DIABETIC 5209.1 14.8 481.5 19.1
NEURO / CNS 4674.1 8.1 410.4 8.5
GYNAECOLOGICAL 4653.3 2.2 383.9 1.8
DERMA 4068.8 10.4 350.3 16.0
OPHTHAL / OTOLOGICALS 1352.0 9.0 110.8 12.4
HORMONES 1257.4 5.4 106.2 7.5
VACCINES 1087.3 -4.3 85.7 -3.3
ANTI-NEOPLASTICS 977.5 21.1 85.2 37.0
OTHERS 912.6 1.9 82.2 18.3
BLOOD RELATED 882.5 2.1 72.1 9.2
ANTI MALARIALS 611.8 0.9 31.2 10.0
SEX STIMULANTS / REJUVENATORS 420.2 5.1 39.0 8.6
STOMATOLOGICALS 334.1 7.5 28.0 9.7
(Express-Pharma-financial, 2014)

Page6
The Credit Suisse report on speciality pharmaceuticals said Sun Pharma,
Glenmark and Lupin have the best overall portfolios in India. Glenmark gets only
one-fourth of its sales from chronic therapies and despite that it has the highest
exposure in the fastest-growing molecules. Sun Pharma too has strong exposure to
high-growth molecules and consistently gained market share across the segments.
Lupin and Glenmark also continued to gain market shares in the highest growth
segment.
Among other leading pharma players, Dr Reddy's, Cadila and Cipla have high
exposure to slow-growing molecules. According to the report, Dr Reddy's, Cipla and
Cadila have almost 60 percent of sales coming from molecules growing less than 15
percent, which explains weak India sales growth for these firms, while leaders like
Dr Reddy's and Ranbaxy slipped on growth trajectory in last two years due to market
share loss.
India has seen the entry of more drugs to tap the fast growing market
for diabetes. Global major - Novo Nordisk and domestic leaders – Lupin, Sun
pharma, Glenmark, Zydus Cadila, Piramal Enterprises, Emcure Pharma are gearing
up with new products, as well as division launches, to grab a bigger pie.
The country, which has about 65 million diabetics, will see the number grow
to 100 million by 2030. Hence, the market is expected to reach Rs 6,500 crore by
2015 from the current size Rs 4,500 crore, a growth of 45 per cent.
Novo Nordisk launched Tresiba, a new basalinsulin for patients with type-I
and type-II diabetes. The company claimed this would offer flexibility in the timing
of insulin administration.

Page7
Apart from nearly 65 million diabetics, India has 77 million pre-diabetics.
About 85-90 per cent of the patients suffer from dyslipidemia or lipid abnormalities,
causing cardiovascular diseases (CVD).
In India, one of every five persons is at serious risk of developing
cardiovascular diseases. It is second to China in number of diabetics across the globe.
Genetically, Indians become diabetic much earlier than their western counterparts.
Nowadays, even children at age of 13-14 are diabetics due to the change in lifestyles
– consumption of junk food, fast food and growing obesity.
Though the market is crowded with drugs for diabetics, drugs with novel
technologies are hitting the market nowadays. Molecules for diabetes act on different
pathways where drug metabolism is changed. One molecule which acts on one may
not work on another patient. This creates enough room for each new drug in India.
Piramal’s molecule- P7435 has been developed by the NCE Research Division of
PEL for the management of metabolic disorders such as lipid abnormalities and
diabetes.
Zydus Cadila has developed a new class of diabetic drug Saroglitazar, branded
as Lipaglyn and received marketing approval from the Drugs Controller General of
India (DCGI) in June. According to Cadila claims, Lipaglyn is the world’s first drug
for treating diabetic dyslipidemia combining lipid and glucose lowering effects in
one single molecule. Diabetic Dyslipidemia is a condition where a person is diabetic
and has elevated levels of the total cholesterol. Recently, Pune-based Emcure has
ventured into diabetic segment by launching Criante, a new diabetic care division.

Page8
1.4.2 Thrombosis Market
With government and industry initiatives working to broaden access to
treatment in India, the introduction and increased availability of anti-thrombotic
drugs is expected to expand exponentially and could be worth USD$272 million by
2016 (IMS Market Prognosis 2012).

Page9
CHAPTER 2: COMPANY PROFILE
2.1 Introduction
Established in the year 2010, we, “Medpaar Pharmaceuticals”, are counted
amongst the prominent suppliers of an extensive range of Health Care Products.
Our range of Health Care Products provides cure to various ailments and
appreciated for its purity, accurate composition & long shelf life. Moreover, our
research and development experts keep them updated with prevailing market trends
and conduct various market survey to ensure that our products are reasonable prices
in the national market. With the support of our well-connected transportation
network, we have been able to ensure the timely delivery of the consignments at the
clients' site. All these attributes have enabled us in acquiring certificate of
registration under Gujarat value added tax act, 2003 and license to manufacture for
sale drugs.
Our owner, 'Mr. Vilesh Patel', holds wide industry experience in the field of
pharmaceutical sector. His excellent administration skills and profound knowledge
has guides us in every sphere of business. Under his able guidance, we have been
able to gain a respectable position of ourselves in this highly competitive industry.
2.2 Company Profile
Business Type •Marketer & Supplier
Ownership & Capital
Year of Establishment •2008
Ownership Type •Partnership Firm
Trade & Market Annual Turnover •Rs. 10-12 million Approx
Total Number of Employees •25 People
Company USP •Provide After Sales Support

 COMPANY PROFILE  CHAPTER 2
Page10
Primary Competitive Advantage •Good Financial Position & TQM
•Good Product Line
Payment Mode •Cash
•Cheque
•Credit Card
•DD
2.3 Company Vision
“We will endeavor to emerge as a leader in the integrated pharmaceuticals
business by continually achieving and surpassing the highest standards in quality".
At Medpaar, we will continuously provide value to all stakeholders of the
organization with a focus on innovation and core values towards achieving
excellence across all operations.
2.4 Company Mission
 Our determined commitment to our values in integrity, transparency and
responsible corporate citizenship along all facets of our value chain
 A continuous focus on achieving excellence and leadership through the
highest standards of quality across all functions of our organization
 Ensuring a safe and healthy environment for all personnel and maintaining
harmony with the natural environment
 Recruiting, training and retain the highest caliber of professionals in the
industry
 To ensure the well-being of the community by effectively fulfilling social
responsibilities

Page11
2.5 Core Values
“Medpaar Pharmaceuticals is an integrity driven organization that focuses on
traditional values coupled with innovative management".
Our core values are defined as follows:
 To Inspire trust through example driven Leadership across all aspects of the
management of our company
 To pursue excellence through a continual focus on quality and innovation
 To emerge as an employer of choice through the best human resource
practices and continuously invest in human capital over the longer term
2.6 Working Strategy
Being a trusted name in the sphere of Health Care Products, we pay immense
attention towards operations, financial stability, growth, market position and long-
term success. From hospital strategy to physician alignment, we assist you in each
and every aspect. In this regard, we have appointed a team of professionals, which
is highly experienced & committed towards providing our clients with efficient
solutions.
It is due to our client-centric approach that we have been able to implement
the plan in the following areas:
• Co-Management physician acquisition
• Alternatives to physician employment
• Practice management
• Physician manpower planning
• Physician compensation
2.7 Our Team
We are supported by a dexterous team of professionals, which is highly skilled
and plays a pivotal role in the consistent growth of our organization. Our

Page12
professionals possess wide industry experience in this domain due to which, we have
been able to provide continuous improvisation in our range.
In our team, we have following professionals:
• Medical experts
• Pharmacists
• Marketing Experts
All these professionals work in harmony with each. They also undergo skill
enhancing training on regular basis to keep them updated with latest market changes
and industrial standards, so as to be ahead of times.
2.8 Product Portfolio
We are a supplier of a comprehensive range of Health Care Products for human
purposes. It is hygienically processed using active ingredients and used for the
treatment of various ailments. Health Care Products offered by us are in compliance
with set industry standards and highly demanded by leading customers based in
pharmaceutical & health care sectors.
2.9 Company product range:
1. Folcymed Tab.
2. Folcymed Z Tab.
3. Calcitar 500 Tab.
4. Laximed Solution
5. Rabidem 20 Tab.
6. Rabidem DSR Cap.
7. Pantodem 40 Tab.
8. Pantodem D Tab.
9. Pantodem DSR Cap.
10.Meditus Tab.

Page13
11.Meditus Cough Syrup
12.Bro-Medex Expectorant
13.Medex Cough Syrup
14.Cefidem 200 DT
15.Safepod DT
16.Safepod Dry Syrup
17.Azidem 250 Tab.
18.Azidem 500 Tab.
19.Flucodem 150 Tab.
20.Levodem 250 Tab.
21.Levodem 500 Tab.
22.Oflodem OZ Tab.
23.Medpar Tab.
24.Medpar SP Tab.
25.Medpar Plus Tab.
26.Medcort Tab.
27.Medcort Suspension
28.Medmarin Suspension
29.Anxypar-0.25 Tab.

Page13
CHAPTER 3: REVIEW OF LITERATURE
Diabetes mellitus is a group of metabolic diseases characterized by
hyperglycemia resulting from defects in insulin secretion, insulin action, or both.
The chronic hyperglycemia of diabetes is associated with long-term damage,
dysfunction, and failure of various organs, especially the eyes, kidneys, nerves,
heart, and blood vessels.
Several pathogenic processes are involved in the development of diabetes.
These range from autoimmune destruction of the β-cells of the pancreas with
consequent insulin deficiency to abnormalities that result in resistance to insulin
action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism
in diabetes is deficient action of insulin on target tissues. Deficient insulin action
results from inadequate insulin secretion and/or diminished tissue responses to
insulin at one or more points in the complex pathways of hormone action.
Impairment of insulin secretion and defects in insulin action frequently coexist in
the same patient, and it is often unclear which abnormality, if either alone, is the
primary cause of the hyperglycemia.
Symptoms of marked hyperglycemia include polyuria, polydipsia, weight
loss, sometimes with polyphagia, and blurred vision. Impairment of growth and
susceptibility to certain infections may also accompany chronic hyperglycemia.
Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia
with ketoacidosis or the nonketotic hyperosmolar syndrome.
Long-term complications of diabetes include retinopathy with potential loss
of vision; nephropathy leading to renal failure; peripheral neuropathy with risk of
foot ulcers, amputations, and Charcot joints; and autonomic neuropathy causing
gastrointestinal, genitourinary, and cardiovascular symptoms and sexual
dysfunction. Patients with diabetes have an increased incidence of atherosclerotic
cardiovascular, peripheral arterial, and cerebrovascular disease. Hypertension and
abnormalities of lipoprotein metabolism are often found in people with diabetes.

 REVIEW OF LITERATURE  CHAPTER 3
Page14
3.1 Type 1 diabetes (β-cell destruction, usually leading to absolute insulin
deficiency) Immune-mediated diabetes[2][18][19]
This form of diabetes, which accounts for only 5–10% of those with diabetes,
previously encompassed by the terms insulin-dependent diabetes, type I diabetes, or
juvenile-onset diabetes, results from a cellular-mediated autoimmune destruction of
the β-cells of the pancreas. Markers of the immune destruction of the β-cell include
islet cell autoantibodies, autoantibodies to insulin, autoantibodies to glutamic acid
decarboxylase (GAD65), and autoantibodies to the tyrosine phosphatases IA-2 and
IA-2β. One and usually more of these autoantibodies are present in 85–90% of
individuals when fasting hyperglycemia is initially detected.
In this form of diabetes, the rate of β-cell destruction is quite variable, being
rapid in some individuals (mainly infants and children) and slow in others (mainly
adults). Some patients, particularly children and adolescents, may present with
ketoacidosis as the first manifestation of the disease. Others have modest fasting
hyperglycemia that can rapidly change to severe hyperglycemia and/or ketoacidosis
in the presence of infection or other stress. Still others, particularly adults, may retain
residual β-cell function sufficient to prevent ketoacidosis for many years; such
individuals eventually become dependent on insulin for survival and are at risk for
ketoacidosis. At this latter stage of the disease, there is little or no insulin secretion,
as manifested by low or undetectable levels of plasma C-peptide. Immune-mediated
diabetes commonly occurs in childhood and adolescence, but it can occur at any age,
even in the 8th and 9th decades of life.
3.2 Type 2 diabetes (ranging from predominantly insulin resistance with
relative insulin deficiency to predominantly an insulin secretory defect with
insulin resistance) [2][18][19]
This form of diabetes, which accounts for ∼90–95% of those with diabetes,
previously referred to as non-insulin-dependent diabetes, type II diabetes, or adult-
onset diabetes, encompasses individuals who have insulin resistance and usually
have relative (rather than absolute) insulin deficiency At least initially, and often
throughout their lifetime, these individuals do not need insulin treatment to survive.
There are probably many different causes of this form of diabetes. Although the

Page15
specific etiologies are not known, autoimmune destruction of β-cells does not occur,
and patients do not have any of the other causes of diabetes.
3.3 Impaired fasting glucose (IFG)[2][18][19]
The Expert Committee (1,2) recognized an intermediate group of subjects
whose glucose levels, although not meeting criteria for diabetes, are nevertheless too
high to be considered normal. This group is defined as having fasting plasma glucose
(FPG) levels ≥100 mg/dl (5.6 mmol/l) but <126 mg/dl (7.0 mmol/l) Thus, the
categories of FPG values are as follows:
FPG <100 mg/dl (5.6 mmol/l) = normal fasting glucose;
FPG 100–125 mg/dl (5.6–6.9 mmol/l) = IFG (impaired fasting glucose);
FPG ≥126 mg/dl (7.0 mmol/l) = provisional diagnosis of diabetes (the
diagnosis must be confirmed)
3.4 Treatment[8][12][13]
Type 2 diabetes mellitus, a disorder of impaired insulin secretion and insulin
resistance, has reached epidemic proportions. The effective management of Type 2
diabetes is of vital concern to clinicians. The identification of high-risk individuals
and lifestyle management can help control diabetes; however, most patients require
pharmacologic intervention. The goals of pharmacologic therapy are to achieve
adequate glycemic control while avoiding hypoglycemia and weight gain and to
minimize the risk of future micro- and macrovascular complications. There are a
number of available glucose-lowering agents from which to choose.
Sometimes blood sugar levels remain high in people with type 2 diabetes even
though they eat in a healthy manner and exercise. When this happens, medications
may be prescribed. The medications work in several different ways. These include
improve the effectiveness of the body's natural insulin, reduce blood sugar
production, increase insulin production and inhibit blood sugar absorption. Some of
the most common types of medication are listed below. They are taken by mouth or
injection.

Page16
Alpha-glucosidase inhibitors
Biguanides
DPP IV inhibitors
Injectable medicines
Meglitinides
Sulfonylureas
Thiazolidinediones
The sulfonylureas, the first oral agents introduced for the management of
Type 2 diabetes, which are effective, well-tolerated, and well-established drugs,
Second-generation sulfonylureas are now widely used in the management of Type 2
diabetes. The most recent addition, glimepiride, can be used in combination with
metformin, the thiazolidinediones, α-glucosidase inhibitors, and insulin.
Glimepiride achieved desirable glycemic control in patients with recent-onset type
2 DM through improvement in insulin secretion and sensitivity. (Kabadi, Mary U.;
Kabadi, Udaya, 2014). The unique properties of glimepiride may provide advantages
over other currently available insulin secretagogues.
Insulin resistance occurs early in type 2 diabetes disease process and may lead
to progressive beta cell failure and overt diabetes (Abdul-Ghani, Tripathy, &
DeFronzo, 2006). Monotherapy can slow down but does not prevent the progression
of the disease. Successful management requires combination therapy that addresses
both insulin resistance and beta cell dysfunction (Cefalu, Waldman, & Ryder, 2007).
Clinical trials support the use of combinations of antidiabetic agents with
complementary mechanisms of action such as ansulfonylurea/metformin (Dailey,
2003; Rendell, 2004).
Metformin and glimepiride seem to be particularly well suited for use in
combination because of their different mechanisms of action. Metformin inhibits
hepatic glucose production and increases the sensitivity of peripheral tissues to
insulin, whereas glimepiride works primarily to increase insulin secretion. These
drugs appear to have complementary effects in improving glycemic control, as well
as beneficial effects on lipids and body weight (DeFronzo & Goodman, 1995). In
one clinical trial of 372 patients, the combination of glimepiride and metformin was

Page17
significantly more effective than either drug alone in reducing A1C concentration or
glucose and PPG levels (Charpentier et al., 2001).
On one hand, glibenclamide+metformin is the oral antidiabetic combination
most used in the clinical practice today (Dailey, 2003); on the other
hand, Glimepiride considered as a third-generation sulfonylurea agent--has several
beneficial pharmacological effects over glibenclamide, a second-generation
sulfonylurea. Glimepiride combined with metformin in a single dose presentation
has proved to be effective and safe for type 2 diabetes patients who fail with
monotherapy on oral antidiabetic agents (González-Ortiz, Martínez-Abundis, &
Grupo para el tratamiento de la diabetes mellitus con combinaciones, 2004).
Glimepiride+metformin showed a greater efficacy in reaching the metabolic
goal of glycemic control with less hypoglycemic events in patients with uncontrolled
type 2 diabetes mellitus in comparison with glibenclamide+metformin. (González-
Ortiz, Nov 2009) In long term diabetes treatment higher doses of insulin and
combined therapy with insulin and metformin may be more beneficial than with low
doses of insulin or sulfonyl urea alone (Sona Valsara, 2009)

Page18
CHAPTER: 4 RESEARCH METHODOLOGY
4.1 Plan of Work
Table 4.1 PLAN OF WORK
4.2 Research objective:-
 To study doctor perception on Glimepiride+Metformin.
 To analyze brand selection criteria for Glimepiride+Metformin.
 To determine which brand is superior according to doctor.
 To analyze the future market demand of Glimepiride+Metformin.
 To determine which strength Glimepiride+Metformin is mostly use.
DATE ACTIVITY
05/12/2013
To
20/01/2014
Medpaar Pharmaceuticals Visit
Selection of project title
Secondary research on internet and questionnaire
formation
23/01/2014 ITD presentation
01/02/2014 Initial survey.
05/03/2014 Survey completion.
07/03/2014 Surveys are reported.
10/03/2014
To
12/03/2014
Complete theoretical portion of the project.
15/03/2014
To
20/03/2014
Data interpretation and analysis.
21/03/2014
To
23/03/2014
Finding and conclusion.
11/04/2014 Finishing project.

 RESEARCH METHODOLOGY  CHAPTER 4
Page19
4.3 Scope of study:-
As we described, I grab the opportunity to get the research work regarding
satisfactory level among the doctors regarding new product launch for type-2
diabetic which contain Glimepiride and Metformin by Medpaar Pharmaceuticals.
Therefore our scope of study is “the doctors’ preference on Glimepiride+Metformin
as the part of pre-launching activity.”
4.4 Research Methodology and Design[15]
 In order to achieve the objectives a survey of Doctors (Physicians, General
Practitioners) was conducted.
 Research Design: Exploratory research.
4.5 Data Collection Sources[15]
 Primary Data:
 Primary data is collected from fieldwork (by using questionnaire).
 Target Population: Doctors (Physicians, General Practitioners)
 Sampling Technique: Convenience Sampling.
 Sample Size: Doctors- 105,
 Sampling Area: North Gujarat Region.
 Secondary Data:
 Secondary data is gathered from internet and books.
4.6 Data Collection and Analysis[15]
 Questionnaire was used to collect data from doctors.
 Data was obtained on the basis of questionnaire filled and personal interview
with the doctors.
 The survey was conducted in various areas of North Gujarat(Mehsana,
Himatnagar, Visnagar, Vijapur)
 Data Analysis is done by SPSS and Microsoft Excel software in computer.

 RESEARCH METHODOLOGY  CHAPTER 4
Page20
4.7 Limitations
 For the study non probability sampling was used and sample may not be a
true representative of the universe.
 Due to the time constraints, sample size was limited to 105 consumers,
which may not be adequate for the generalization of the findings.
 Study was carried out in North Gujarat region only so conclusion can’t be
drawn for the whole state.
 Unwillingness of doctors to give response.

Page21
CHAPTER 5: DATA ANALYSIS
5.1 Demographic Characteristics:
Figure 5.1 SAMPLE DISTRIBUTION (AREA)
Figure 5.2 SAMPLE DISTRIBUTION (GENDERWISE) Figure 5.3 SAMPLE DISTRIBUTION (AGEWISE)
34
12
8
20
11
8
2
10
0
5
10
15
20
25
30
35
40
MEHSANA VISNAGAR VIJAPUR HIMATNAGAR
NO.OFDOCTORS
PLACE
SAMPLE DISTRIBUTION (AREA)
MD
GP
93%
7%
GENDER
MALE FEMALE
34%
66%
0%0%
AGE
20-40 YEARS 40-60 YEARS ABOVE 60 YEARS

 DATA ANALYSIS  CHAPTER 5
Page22
5.2 Patient Consulting During a Day:
Table 5.1 RECOMANDED DATA (PATIENT CONSULTING DURING A DAY)
Patient consulting during a day Frequency Percent Cumulative Percent
1 TO 20
21 TO 40
41 TO 60
61 TO 80
0
0
2
14
0.0
0.0
1.9
13.3
0.0
0.0
1.9
15.2
MOTE THAN 81 89 84.8 100.0
Total 100 100.0
Figure 5.4 RECOMANDED DATA ANALYSIS (PATIENT CONSULTING DURING A DAY)
INTERPRETATION: During research it was found that in a day 84.8% of
doctors are consulting more than 80 patients, 13.3% of doctors consulting 61 to 80
patients and 1.9% of doctors consulting 41 to 60 patients.
0 0 2
14
89
0
10
20
30
40
50
60
70
80
90
100
1 TO 20 21 TO 40 41 TO 60 61 TO 80 MOTE THAN 81
NO.OFDOCTORS
NO. OF PATIENT
PATIENT CONSULTING DURING A DAY
NO. OF DOCTORS

Page23
5.3 Consulting Diabetic Patient during a Day:
Table5.2 RECOMMANDED DATA (CONSULTING DIABETIC PATIENT DURING A DAY)
CONSULTING DIABETIC
PATIENT DURING A DAY
Frequency Percent Cumulative
Percent
1 TO 5 8 7.6 7.6
6 TO 10 21 20.0 27.6
11 TO 15 64 61.0 88.6
16 TO 20 7 6.7 95.2
MORE THAN 21 5 4.8 100.0
Total 100 100.0
Figure 5.5 RECOMMANDED DATA ANALYSIS (CONSULTING DIABETIC PATIENT DURING A DAY)
INTERPRETATION: During research it was found that in a day 61% of doctors
consults average 11-15 diabetic patients, 20% of doctors consult 6-10 diabetic
patients, 7.6% of doctors consult 1-5 diabetic patients, 6.7% of doctors consult 16-
20 diabetic patients and 4.8% of doctors consult more than 21 diabetic patients.
8
21
64
7
5
0
10
20
30
40
50
60
70
1 TO 5 6 TO 10 11 TO 15 16 TO 20 MORE THAN 21
NO.OFDOCTORS
NO. OF DIABETIC PATIENT
CONSULTING DIABETIC PATIENT DURING A DAY
NO. OF DOCTORS

Page24
5.4 Mostly Prescribe Drug For Type-2 Diabetic Mellitus:
Table 5.3 RECOMMANDED DATA (MOSTLY PRESCRIBE DRUG FOR TYPE 2 DIABETES)
MOSTLY PRESCRIBE DRUG FOR
TYPE 2 DIABETES
Percent
GLIMEPIRIDE 29 27.6 27.6
METFORMIN 35 33.3 61.0
GLIMEPIRIDE+METFORMIN 17 16.2 77.1
PIOGLITAZONE 10 9.5 86.7
SITAGLIPTIN 2 1.9 88.6
OTHER 12 11.4 100.0
Total 105 100.0
Figure 5.6 RECOMMANDATION DATA ANALYSIS (MOSTLY PRESCRIBE DRUG FOR TYPE 2 DIABETES)
GLIMEPIRIDE
METFORMIN
GLIMEPIRIDE+METFOR
MIN
PIOGLITAZONE
SITAGLIPTIN
OTHER
MOSTLY PRESCRIBE DRUG FOR TYPE 2 DIABETES
GLIMEPIRIDE
METFORMIN
GLIMEPIRIDE+METFORMIN
PIOGLITAZONE
SITAGLIPTIN
OTHER

Page25
INTERPRETATION: During research it was found that 33.3% doctors prescribe
Metformin, 27.6% doctors prescribe Glimepiride, 16.2% doctors prescribe
Metformin + Glimepiride, 9.5% doctors prescribe Pioglitazone, 6.66% doctors
prescribe Acarbose, 4.76% doctors prescribe Voglibose and 1.9% doctors prescribe
Sitagliptin.

Page26
5.5 Reason For Prescribing Glimepiride+Metformin Combination:
Table 5.4 RECOMMANDED DATA (REASON FOR PRESCRIBING GLLIMEPIRIDE+METFORMIN COMBINATION)
REASON FOR PRESCRIBING
GLLIMEPIRIDE+METFORMIN
COMBINATION
Percent
MAXIMUM THERAPEUTIC
EFFECT
88 83.8 83.8
RAPID ACTION 17 16.2 100.0
MINIMUM SIDE EFFECT 0 0.0 100.0
ALL THREE 0 0.0 100.0
Total 105 100.0
Figure 5.7 RECOMMANDED DATA ANALYSIS (REASON FOR PRESCRIBING GLLIMEPIRIDE+METFORMIN)
this combination because of maximum therapeutic effect, 16.2% doctors prescribe
this combination because of rapid action.
88
17
0 0
0
10
20
30
40
50
60
70
80
90
100
MAXIMUM
THERAPEUTIC
EFFECT
RAPID ACTION MINIMUM SIDE
EFFECT
ALL THREE
NO.OFDOCTORS
REASON FOR PRESCRIBING METFORMIN+GLIMEPIRIDE
REASON FOR PRESCRIBING METFORMIN+GLIMEPIRIDE
NO. OF DOCTORS

Page27
5.6 More Prefer Brand for Glimepiride+Metformin:
Table 5.5 RECOMMANDED DATA (MORE PREFER BRANDFOR GLLIMEPIRIDE+METFORMIN)
MORE PREFER BRAND FOR
Percent
GLIMESTAR-M 7 6.7 6.7
GLIMY-M 6 5.7 12.4
GLISTA 3 2.9 15.2
GEMER 20 19.0 34.3
GLUCONORM-G 14 13.3 47.6
OTHERS
(ZORYL,
GLYCOMET GP,
ZIGLIM)
55
(ZOR-25)
(GLY-25)
(ZIG-5)
52.4
(23.80)
(23.80)
(4.76)
100.0
Total 105 100.0
Figure 5.8 RECOMMANDED DATA ANALYSIS (MORE PREFER BRAND OF GLLIMEPIRIDE+METFORMIN)
7 6
3
20
14
55
0
10
20
30
40
50
60
NO.OFDOCTORS
METFORMIN+GLIMEPIRIDE BRANDS
MORE PREFER BRANDS OF METFORMIN+GLIMEPIRIDE
NO. OF DOCTORS

Page28
INTERPRETATION: During research it was found that 52.4% doctors preferred
other brands, 19% doctors preferred Gemer (Sun), 13.3% doctors preferred
Gluconorm-G (Lupin), 6.7% doctors preferred Glimestsr-M (Mankind), 5.7%
doctors preferred Glimy-M (Dr. Reddy) and 2.9% doctors preferred Glista
(Cadila).

Page29
5.7 Most Prescribing Strength of Gllimepiride+Metformin:
Table 5.6 RECOMMANDED DATA (MOST PRESCRIBING STRENGTH OF GLLIMEPIRIDE+METFORMIN)
MOSTLY PRESCRIBE
STRENGTH
Frequency Percent Cumulative Percent
GLIMEPIRIDE-1MG +
METFORMIN-500MG 77 73.3 73.3
GLIMEPIRIDE-2MG+
METFORMIN-500MG 8 7.6 81.0
GLIMEPIRIDE-1MG +
METFORMIN-1000MG 20 19.0 100.0
GLIMEPIRIDE-4MG +
METFORMIN-1000MG 0 0.0 100.0
GLIMEPIRIDE-1MG +
METFORMIN-850MG 0 0.0 100.0
Total 105 100.0
Figure 5.9 RECOMMANDED DATA ANALYSIS (MOST PRESCRIBING STRENGTH OF GLLIMEPIRIDE+METFORMIN)
Glimepiride-1mg+Metformin-500mg, 7.6% doctors prescribe Glimepiride-
2mg+Metformin-500mg and 19% doctors prescribe Glimepiride-1mg+Metformin-
77
8
20
0 0
0
10
20
30
40
50
60
70
80
90
GLIMEPIRIDE-1MG +
METFORMIN-500MG
GLIMEPIRIDE-2MG+
METFORMIN-500MG
GLIMEPIRIDE-1MG +
METFORMIN-1000MG
GLIMEPIRIDE-4MG +
METFORMIN-1000MG
GLIMEPIRIDE-1MG +
METFORMIN-850MG
NO.OFDOCTORS
PRESCRIBING STRENGTH
PRESCRIBE STRENGTH OF METFORMIN+GLIMEPIRIDE
NO. OF DOCTORS

Page30
1000mg.It is indicate the highest demand of Glimepiride-1mg+Metformin-500mg
strength in the market.

Page31
5.8 Adverse Reaction with Glimepiride+Metformin:
Table 5.7 RECOMMANDED DATA (ADVERSE REACTION WITH GLLIMEPIRIDE+METFORMIN)
ADVERSE REACTION WITH
Percent
YES 47 44.8 44.8
NO 58 55.2 100.0
Total 105 100.0
Figure 5.10 RECOMMANDED DATA ANALYSIS (ADVERSE REACTIONS WITH GLLIMEPIRIDE+METFORMIN)
INTERPRETATION: During research it was found that 55.2% doctors have not
find adverse reactions with this combination and 44.8% doctors find adverse
reactions with this combination due to patient incompatibility with drug. Generally
hypoglycemia & stomach pain occur in patient of type 2 diabetes as adverse
reaction.
45%
YES55%
NO
0%0%
ADVERSE REACTIONS WITH
METFORMIN+GLIMEPIRIDE
YES
NO

Page32
5.9 Opinion on Future Demand of Glimepiride+Metformin:
Table 5.8 RECOMMANDED DATA (OPINION ON FUTURE DEMAND)
OPINION ON FUTURE
DEMAND
Percent
VERY HIGH DEMAND 0 0.0 0.0
HIGH DEMAND 73 69.5 69.5
AVERAGE DEMAND 32 30.5 100.0
LOW DEMAND 0 0.0 100.0
VERY LOW DEMAND 0 0.0 100.0
Total 105 100.0
Figure 5.11 RECOMMANDED DATA ANALYSIS (OPINION ON FUTURE DEMAND)
INTERPRETATION: During research it was found that 69.5% doctors have
opinion to high future demand of this combination and 30.5% doctors have opinion
to average demand of this combination. It is indicate chance to launch new brand
of Glimepiride+Metformin due to high demand in future.
73
32
0 0
0
10
20
30
40
50
60
70
80
VERY
HIGH DEMAND
HIGH DEMAND AVERAGE
DEMAND
LOW DEMAND VERY LOW
DEMAND
NO.OFDOCTORS
FUTURE DEMAND
OPINION ON FUTURE DEMAND OF
METFORMIN+GLIMEPIRIDE
NO. OF DOCTORS

Page33
5.10 Preference to Select Company:
5.10.1 Regular visit of Medical Representative:
Table 5.9 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-REGULAR VISIT OF MR)
REGULAR VISIT OF MR Frequency Percent Cumulative
Percent
HIGHLY PREFERRED 95 90.5 90.5
PREFERRED 8 7.6 98.1
MODERATELY
PREFERRED
2 1.9 100.0
LESS PREFERRED 0 0.0 100.0
NOT PREFERRED 0 0.0 100.0
Total 105 100.0
Figure 5.12 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-REGULAR VISIT OF MR)
INTERPRETATION: During research it was found that 90.5% doctors highly
prefers and 7.6% doctors prefers regular visit of MR for selection of company,
1.9% doctors moderately prefers regular visit of MR for selection of company.
95
8
2 0 0
0
10
20
30
40
50
60
70
80
90
100
HIGHLY
PREFERRED
PREFERRED MODERATELY
PREFERRED
LESS
PREFERRED
NOT
PREFERRED
NO.OFDOCTORS
PREFERENCE OF SELECTION
REGULAR VISIT OF MR
NO. OF DOCTORS

Page34
5.10.2 Samples:
Table 5.10 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-SAMPLES)
SAMPLES Frequency Percent Cumulative
Percent
MODERATELY
PREFERRED
5 4.8 95.2
Total 105 100.0
Figure 5.13 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-SAMPLES)
prefer and 12.4% doctors prefer to consider samples for selection of company,
4.8% doctors moderately prefer samples while 4.8% doctors less prefer to consider
samples for selection of company.
82
13
5 5
0
10
20
30
40
50
60
70
80
90
HIGHLY PREFERRED PREFERRED MODERATELY
PREFERRED
LESS PREFERRED
NO.OFDOCTORS
SAMPLES PROVIDED BY COMPANY
NO. OF DOCTORS

Page35
5.10.3 Knowledge update program by the company:
Table 5.11 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-KNOWLEDGE UPDATE PROGRAM)
KNOWLEDGE UPDATE PROGRAM
BY THE COMPANY
Percent
MODERATELY
PREFERRED
11 10.5 94.3
Total 105 100.0
Figure 5.14 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-KNOWLEDGE UPDATE PROGRAM)
prefer and 11.4% doctors prefer to consider knowledge update program for
selection of company, 10.5% doctors moderately prefer to consider knowledge
update program for selection of company while 5.7% doctors less prefer to
consider knowledge update program for selection of company.
76
12 11
6
0
0
10
20
30
40
50
60
70
80
HIGHLY
PREFERRED
PREFERRED
LESS
PREFERRED
NOT
PREFERRED
NO.OFDOCTORS
KNOWLEDGE UPDATE PROGRAM BY THE COMPANY
NO. OF DOCTORS

Page36
5.10.4 Scientific literature provided by company:
Table 5.12 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-SCIENTIFIC LITERATURE BY COMPANY)
SCIENTIFIC LITERATURE
PROVIDED BY COMPANY
Percent
MODERATELY
PREFERRED
3 2.9 98.1
Total 105 100.0
Figure 5.15 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-SCIENTIFIC LITERATURE BY COMPANY)
prefer and 19% doctors prefer to consider scientific literature provided by company
for selection of brand, 2.9% doctors moderately preferred to consider scientific
literature provided by company for selection of brand while 1.9% doctors less
prefer to consider scientific literature for selection of company.
80
20
3 2 0
0
10
20
30
40
50
60
70
80
90
HIGHLY
PREFERRED
PREFERRED
LESS
PREFERRED
NOT
PREFERRED
NO.OFDOCTORS
SCIENTIFIC LITERATURE PROVIDED BY COMPANY
NO. OF DOCTORS

Page37
5.10.5 Scientific support from company:
Table 5.13 RECOMMANDED DATA (PREFERENCE TO SELECT COMPANY-SCIENTIFIC SUPPORT FROM COMPANY)
SCIENTIFIC SUPPORT FROM
COMPANY
Percent
MODERATELY
PREFERRED
15 14.3 95.2
Total 105 100.0
Figure 5.16 RECOMMANDED DATA ANALYSIS (PREFERENCE TO SELECT COMPANY-SCIENTIFIC SUPPORT FROM COMPANY)
prefer and 22.9% doctors prefer to consider scientific support from company for
selection of brand, 14.3% doctors moderately prefer to consider scientific support
from company for selection of brand while 4.8% doctors less prefer to consider
scientific support for selection of company.
61
24
15
5
0
0
10
20
30
40
50
60
70
HIGHLY
PREFERRED
PREFERRED
LESS
PREFERRED
NOT
PREFERRED
NO.OFDOCTORS
SCIENTIFIC SUPPORT FROM COMPANY
NO. OF DOCTORS

Page38
5.10.11 All criteria for selection of company
Table 5.14 RECOMMANDED DATA (OVERALL PREFERENCE FOR SELECTION OF COMPANY)
Criteria Highly
Preferred
Preferred Moderately
Preferred
Less
Preferred
Not
Preferred
Avg.
score
Regular visit of MR 95 8 2 0 0 4.88
Samples 82 13 5 5 0 4.63
Knowledge update
program by the
company
76 12 11 6 0 4.50
Scientific literature
provided by company
80 20 3 2 0 4.69
Scientific support
provided by company
61 24 15 5 0 4.34
Figure 5.17 RECOMMANDED DATA ANALYSIS (OVERALL PREFERENCE FOR SELECTION OF COMPANY)
INTERPRETATION: During research it was found that doctors consider regular
MR visit (97.6%) for selection of company. That is followed by scientific literature
4.88
4.63
4.5
4.69
4.34
4
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
4.9
5
Regular visit of MR Samples Knowledge update
program by the
company
provided by
company
Scientific support
provided by
company
OVERALL PREFERENCE FOR SELECTION OF COMPANY
AVG. SCORE

Page39
provided by company (93.8%), samples (92.6%), knowledge update program
(90%) and scientific support from company (86.8%).

Page40
5.11 Considering Factors for Brand Selection:
5.11.1 Price:
Table 5.15 RECOMMANDED DATA (BRAND SELECTION-PRICE)
PRICE Frequency Percent Cumulative
Percent
MODERATELY
PREFERRED
1 0.9 41.9
Total 105 100.0
Figure 5.18 RECOMMANDED DATA ANALYSIS (BRAND SELECTION-PRICE)
prefer and 17.1% doctors prefer to consider price as important factor for brand
selection.0.9% doctors moderately prefer to consider price for brand selection.
While 20% doctors less prefer and 38.1% doctors don’t prefer to consider price as
an important factor during brand selection.
25
18
1
21
40
0
5
10
15
20
25
30
35
40
45
HIGHLY
PREFERRED
PREFERRED
LESS
PREFERRED
NOT
PREFERRED
NO.OFDOCTORS
BRAND SELECTION-PRICE
NO. OF DOCTORS

Page41
5.11.2 Company image:
Table 5.16 RECOMMANDED DATA (BRAND SELECTION-COMPANY IMAGE)
COMPANY IMAGE Frequency Percent Cumulative
Percent
N
MODERATELY
PREFERRED
12 11.4 92.4
Total 105 100.0
Figure 5.19 RECOMMANDED DATA ANALYSIS (BRAND SELECTION-COMPANY IMAGE)
prefer and 9.5% doctors prefer to consider company image in brand selection.
11.4% doctors moderately prefer to consider company image in brand selection.
While 7.6% doctors less prefer to consider company image in brand selection.
75
10 12
8
0
0
10
20
30
40
50
60
70
80
HIGHLY
PREFERRED
PREFERRED
LESS
PREFERRED
NOT
PREFERRED
NO.OFDOCTORS
BRAND SELECTION-COMPANY IMAGE
NO. OF DOCTORS

Page42
5.11.3 Availability:
Table 5.17 RECOMMANDED DATA (BRAND SELECTION-AVAILABILITY)
AVAILABILITY Frequency Percent Cumulative
Percent
PREFERRED 1 0.9 0.9
MODERATELY
PREFERRED
3 2.9 3.8
Total 105 100.0
Figure 5.20 RECOMMANDED DATA ANALYSIS (BRAND SELECTION-AVAILABILITY)
INTERPRETATION: During research it was found that 0.9% doctors prefer to
consider availability in brand selection. 2.9% doctors moderately prefer to consider
availability in brand selection. 14.3% doctors less prefer while 85.7% doctors not
prefer to consider availability in brand selection.
0 1 3
11
90
0
10
20
30
40
50
60
70
80
90
100
HIGHLY
PREFERRED
PREFERRED
LESS
PREFERRED
NOT
PREFERRED
NO.OFDOCTORS
BRAND SELECTION-AVAILABILITY
NO. OF DOCTORS

Page43
5.11.4 Effectiveness:
Table 5.18 RECOMMANDED DATA (BRAND SELECTION-EFFECTIVENESS)
EFFECTIVENESS Frequency Percent Cumulative
Percent
MODERATELY
PREFERRED
5 4.8 32.4
Total 105 100.0
Figure 5.21 RECOMMANDED DATA ANALYSIS (BRAND SELECTION-EFFECTIVENESS)
prefer and 18.1% doctors prefer to consider effectiveness in brand selection. 4.8%
doctors moderately prefer to consider effectiveness in brand selection. While
67.6% doctors less prefer to consider effectiveness in brand selection.
10
19
5
71
0
0
10
20
30
40
50
60
70
80
HIGHLY
PREFERRED
PREFERRED
LESS
PREFERRED
NOT
PREFERRED
NO.OFDOCTORS
BRAND SELECTION-EFFECTIVENESS
NO. OF DOCTORS

Page44
5.11.5 Unique tablet formulation:
Table 5.19 RECOMMANDED DATA (BRAND SELECTION-UNIQUE TABLET FORMULATION)
UNIQUE TABLET
FORMULATION
Percent
PREFERRED 0 0.0 0.0
MODERATELY
PREFERRED
1 0.9 0.9
Total 105 100.0
Figure 5.22 RECOMMANDED DATA (BRAND SELECTION-UNIQUE TABLET FORMULATION)
INTERPRETATION: During research it was found that 0.9% doctors moderately
prefer to consider unique tablet formulation in brand selection. 1.9% doctors less
prefers while 97.1% doctors don’t prefer to consider unique tablet formulation in
brand selection.
0 0 1 2
102
0
20
40
60
80
100
120
HIGHLY
PREFERRED
PREFERRED
LESS
PREFERRED
NOT
PREFERRED
NO.OFDOCTORS
BRAND SELECTION-UNIQUE TABLET FORMULATION
NO. OF DOCTORS

Page45
5.11.6 Overall preference for selection of Glimepiride+Metformin brand:
Table 5.20 RECOMMANDED DATA (OVERALL PREFERENCE FOR BRAND SELECTION)
Factors Highly
Preferred
Preferred
Less
Preferred
Not
Preferred
Avg.
Score
Price 25 18 1 21 40 2.68
Company image 75 10 12 8 0 4.44
Availability 0 1 3 11 90 1.19
Effectiveness 10 19 5 71 0 2.69
Unique tablet
formulation
0 0 1 2 102 1.03
Figure 5.23 RECOMMANDED DATA (OVERALL PREFERENCE FOR BRAND SELECTION)
INTERPRETATION: During research it was found that doctors highly prefer to
consider company image (88.8%) for brand selection. That is followed by
effectiveness (53.8%), price (53.6%), availability (23.8%) and scientific unique
tablet formulation (20.6%).
2.68
4.44
1.19
2.69
1.03
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Price Company image Availability Effectiveness Unique tablet
formulation
AVG.SCORE
FACTORS FOR BRAND SELECTION
OVERALL PREFERENCE FOR BRAND SELECTION
AVG. SCORE

Page46
CHAPTER 6: FINDINGS
 About 16% doctors use Glimepiride+Metformin for type-2 diabetes
mellitus.
 For selection of Glimepiride+Metformin brand doctors mostly prefer
company image, effectiveness and price of the product.
 Most of doctors about 23% each prescribe Zoryl (Intas) and Glycomet GP
(USV) brands and mostly doctors prescribe this brand because of good
efficiency.
 Mostly use Glimepiride+Metformin strength in market is Glimepiride-
1mg+Metformin-500mg.
 Glimepiride+Metformin future demand is high as per the doctors’ opinion.
 About 45% doctors find adverse reactions like hypoglycemia and stomach
pain with Glimepiride+Metformin.

Page47
CHAPTER 7: CONCLUSION
I made survey of 105 doctors from North region of Gujarat and study some
literature and find that diabetic patient is increase day by day it is indicate demand
for anti-diabetic drugs is increase day by day.
After market survey I can conclude that demand of Glimepiride+Metformin
is high and mostly doctors prescribe Glimepiride-1mg+Metformin-500mg in type-2
diabetic mellitus. So, company should produce this strength of
Glimepiride+Metformin for sustain in market and improve selling of product.
Regular visit of MR to doctors as well as scientific literature, samples and
effectiveness of product should be maintained because doctors are select company
and product on the basis of these criteria.

Page48
CHAPTER 8: SUGGESTIONS
 Product should be easily available in market and product should have good
effectiveness, it is important for new lunched product.
 Good efficiency of product should be maintained is important for attracting
the doctors to prescribe product.
 For promotional strategy providing adequate literature and covering all
Doctors and introduce product to them was most important for improving sell
of product.
 Company should produce Glimepiride-1mg+Metformin-500mg strength
because this strength is mostly prescribe by the doctors.

Page49
CHAPTER 9: REFERENCE
1. Abdul-Ghani MA, Tripathy D, DeFronzo RA: Contribution of B-cell dysfunction and
insulin resistance to the pathogenesis of impaired glucose tolerance and impaired
fasting glucose. Diabetes Care 29 1130-1139, 2006.
2. American Diabetes Association: Standards of medical care in diabetes--2008. Diabetes
Care 31 S12-S54, 2008.
3. Cefalu WT, Waldman S, Ryder S: Pharmacotherapy for the treatment of patients with
type 2 diabetes mellitus: Rationale and specific agents. Clinical Pharmacology and
Therapeutics 81 636-649, 2007.
4. Dailey GE: Glyburide/metformin tablets: A new therapeutic option for the management
of type 2 diabetes. Expert Opinion on Pharmacotherapy 4 1417-1430, 2003.
5. González-Ortiz M, Martínez-Abundis E: Eficacia y seguridad de la terapia
hipoglucemiante oral combinada de glimepirida más metformina en una sola forma
farmacéutica en pacientes con diabetes mellitus tipo 2 y falla secundaria a monoterapia
con glibenclamida . Revista de Investigacion Clinica 56 327-333, 2004.
6. González-Ortiz, Manuel; Guerrero-Romero, Jesús F.; Violante-Ortiz, Rafael; Wacher-
Rodarte, NielsView Profile; Martínez-Abundis, Esperanza; et al.: Efficacy of
glimepiride/metformin combination versus glibenclamide/metformin in patients with
uncontrolled type 2 diabetes mellitus: Journal of Diabetes and its Complications 376-9
,Nov 2009
7. http://archive.indianexpress.com/news/indias-diabetes-drugs-market-grew-22--at--
700-mn/963511
8. http://care.diabetesjournals.org/content/31/Supplement_1/S55.full
9. http://hosted.comm100.com/knowledgebase/Top-10-therapeutic-segments-in-India-
by-market-value-and-growth_A72.aspx
10. http://www.business-standard.com/article/companies/pharma-giants-ready-to-
harness-diabetes-market-113090300181_1.html
11. http://www.marketresearch.com/Netscribes-India-Pvt-Ltd-v3676/Anti-Diabetic-
Pharmaceuticals-India-6881080
12. http://www.ucsfhealth.org/conditions/diabetes_mellitus/treatment.html

 REFERENCE  CHAPTER 9
Page50
13. K.D Tripathi, Essential of Medical Pharmacology. 6th edition. 2009: Jaypee brothers
medical publishers ltd.
14. Kabadi, Mary U.; Kabadi, Udaya M. Effects of glimepiride on insulin secretion and
sensitivity in patients with recently diagnosed type 2 diabetes mellitus: Clinical
Therapeutics: 63-9, Jan 2014
15. Naresh K. Malhotra, D.F.B., Marketing Research. 3rd ed. 2007: Pearson Education Inc.
16. Rendell M: The role of sulphonylureas in the management of type 2 diabetes mellitus.
Drugs 64 1339-1358, 2004.
17. Sona Valsaraj, K T Augusti, Varghese Chemmanam* and Regi Jose: EFFECTS OF
INSULIN, GLIMEPIRIDE AND COMBINATION THERAPY OF INSULIN AND
METFORMIN ON BLOOD SUGAR AND LIPID PROFILE OF NIDDM PATIENTS:
Indian Journal of Clinical Biochemistry, 2009 / 24 (2) 175-178
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:
Report of the Expert Committee on the Diagnosis and Classification of Diabetes
Mellitus. Diabetes Care 20: 1183–1197, 1997
19. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus:
Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160–3167,
2003

Page51
APPENDIX-I
QUESTIONNAIRE
Dear respondent,
I am Amitsinh Vihol the student of KADI SARVA VISHWAVIDYALAYA MBA
PHARMA, GANDHINAGAR. As a part of management studies requirement in MBA (PHARMA),
I have to submit a project report based on marketing research. In this context I am doing research
on MARKET SURVEY OF DOCTOR PREFERENCE ON
GLIMEPIRIDE+METFORMIN AS A PART OF PRELAUNCH ACTIVITY AT
MEDPAAR PHARMACEUTICALS. I request you to fill up this questionnaire and help me
in my studies. I assure you that this information will be used for academic purpose only.
1. How many patients do you consult during the day?
a. 1 to 20
b. 21 to 40
c. 41 to 60
d. 61 to 80
e. More than 80
2. How many patients do you consult related to type-2 diabetes mellitus during the day?
a. 1 to 5
b. 6 to 10
c. 11 to 15
d. 16 to 20
e. More than 20
3. Which drug do you mostly prescribe for type-2 diabetic mellitus?
a. Glibenclamide
b. Glimepiride
c. Metformin
d. Glimepiride+Metformin
e. Pioglitazone
f. Rosiglitazone
g. Sitagliptin
h. Other______________________

APPENDIX-I
Page52
4. Why do you prescribe Glimepiride+Metformin instead of other anti-diabetic drugs?
a. Maximum therapeutic effect
b. Rapid action
c. Minimize side effect
d. All a, b and c
5. Which brand do you more prefer for Glimepiride+Metformin?
a. Glimestar-M
b. Glimy-M
c. Glista
d. Gemer
e. Gloconorm-G
f. Other______________________
6. Which strength do you mostly prescribe the Glimepiride+Metformin?
a. Glimepiride-1mg , Metformin-500mg
b. Glimepiride-2mg , Metformin-500mg
c. Glimepiride-1mg , Metformin-1000mg
d. Glimepiride-4mg , Metformin-1000mg
e. Glimepiride-1mg , Metformin-850mg
f. Other_______________________
7. Do you find any adverse reaction with Glimepiride+Metformin?
a. Yes
b. No
8. Your opinion on future demand of Glimepiride+Metformin.
Very High
Demand
High
Demand
Average
Demand
Low
Demand
Very Low
Demand
1 2 3 4 5

APPENDIX-I
Page53
9. What is your preference to selection of company?
Criteria Highly
Preferred
Preferred
Less
Preferred
Not
Preferred
Regular visit of MR
Samples
Knowledge update
program by the company
provided by company
Scientific support provided
by company
10. Which factor do you consider for selection of Glimepiride+Metformin brand?
Criteria Highly
Preferred
Preferred
Less
Preferred
Not
Preferred
Price
Company image
Availability
Effectiveness
Unique tablet
formulation

APPENDIX-I
Page54
Demographic Factors
1) Name:-
2) Age:-
– 40 years
- 60 years
years
3) Sex:-
4) Specification: …………………
5) Place: …………………..

Prelaunch activity of Metformin+Glimepiride combination

Recomendados

Recomendados

Más contenido relacionado

La actualidad más candente

La actualidad más candente (20)

Destacado

Destacado (20)

Similar a Prelaunch activity of Metformin+Glimepiride combination

Similar a Prelaunch activity of Metformin+Glimepiride combination (20)

Más de Amitsinh Vihol

Más de Amitsinh Vihol (6)

Último

Último (20)

Prelaunch activity of Metformin+Glimepiride combination